Comparing Two Doses of Glatiramer Acetate

- Relapsing Remitting Multiple Sclerosis
- Completed

Study Title: Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).

Teva Identifier: GA/9016 (FORTE)

ClinicalTrials.gov Identifier: NCT00337779

Study Status: Completed

Trial Condition(s): Relapsing Remitting Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate (GA) 40 mg | Drug: glatiramer acetate 20 mg

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 55 Years

Trial Duration: 08/01/2006 - 10/01/2008

Phase: Phase 3

Study Type

Interventional